46.70
price up icon4.17%   1.87
after-market Dopo l'orario di chiusura: 46.70
loading
Precedente Chiudi:
$44.83
Aprire:
$44.54
Volume 24 ore:
994.02K
Relative Volume:
2.12
Capitalizzazione di mercato:
$2.65B
Reddito:
$29.40M
Utile/perdita netta:
$-352.62M
Rapporto P/E:
-11.82
EPS:
-3.95
Flusso di cassa netto:
$-318.99M
1 W Prestazione:
-0.28%
1M Prestazione:
+13.01%
6M Prestazione:
+35.21%
1 anno Prestazione:
+107.65%
Intervallo 1D:
Value
$43.25
$46.79
Intervallo di 1 settimana:
Value
$43.25
$47.21
Portata 52W:
Value
$20.40
$53.28

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
Nome
Agios Pharmaceuticals Inc
Name
Telefono
617-649-8600
Name
Indirizzo
88 SIDNEY STREET, CAMBRIDGE, MA
Name
Dipendente
386
Name
Cinguettio
@AgiosPharma
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
AGIO's Discussions on Twitter

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-02-08 Iniziato Cantor Fitzgerald Overweight
2023-02-03 Iniziato Piper Sandler Overweight
2022-11-17 Aggiornamento Goldman Sell → Neutral
2022-07-27 Aggiornamento SVB Leerink Mkt Perform → Outperform
2021-12-03 Iniziato BofA Securities Buy
2021-07-30 Downgrade Goldman Neutral → Sell
2021-07-01 Iniziato Raymond James Mkt Perform
2021-06-10 Iniziato H.C. Wainwright Buy
2021-03-01 Downgrade JP Morgan Overweight → Neutral
2021-03-01 Aggiornamento SVB Leerink Mkt Perform → Outperform
2021-02-26 Downgrade SVB Leerink Outperform → Mkt Perform
2020-10-22 Aggiornamento Barclays Equal Weight → Overweight
2020-03-04 Iniziato Barclays Equal Weight
2019-11-26 Iniziato Cantor Fitzgerald Overweight
2019-09-23 Aggiornamento Guggenheim Neutral → Buy
2019-05-23 Ripresa Goldman Neutral
2019-02-15 Aggiornamento SVB Leerink Mkt Perform → Outperform
2018-09-25 Iniziato Leerink Partners Mkt Perform
2018-05-23 Iniziato Citigroup Buy
2018-04-11 Reiterato Credit Suisse Outperform
2018-02-15 Reiterato Needham Buy
2018-02-15 Reiterato SunTrust Buy
2017-09-15 Iniziato RBC Capital Mkts Outperform
2017-08-10 Reiterato Needham Buy
2017-08-08 Reiterato SunTrust Buy
2017-08-02 Aggiornamento Leerink Partners Mkt Perform → Outperform
2017-06-26 Downgrade Janney Buy → Neutral
2017-01-17 Aggiornamento Oppenheimer Perform → Outperform
2016-10-24 Iniziato Needham Buy
2016-06-13 Aggiornamento JP Morgan Neutral → Overweight
2016-05-18 Reiterato SunTrust Buy
Mostra tutto

Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie

pulisher
09:32 AM

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition - The Manila Times

09:32 AM
pulisher
09:05 AM

Agios to Unveil Critical Phase 3 Data for Blood Disorder Drugs at ASH 2024 | AGIO Stock News - StockTitan

09:05 AM
pulisher
06:34 AM

Agios Pharmaceuticals' SWOT analysis: promising pipeline, cash boost fuel stock outlook - Investing.com

06:34 AM
pulisher
Nov 04, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Rating Lowered to “Sell” at StockNews.com - Defense World

Nov 03, 2024
pulisher
Nov 02, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded to "Sell" Rating by StockNews.com - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Given New $53.00 Price Target at Scotiabank - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Agios shares hold Strong Buy rating, $51 target from Raymond James - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and Strategic Advancements - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals: Q3 Earnings Snapshot - The Advocate

Nov 01, 2024
pulisher
Nov 01, 2024

Agios Pharmaceuticals Reports Robust Q3 2024 Results - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings: EPS Surpasses Estimates, Revenue at $9.0 Million - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Agios Reports Business Highlights and Third Quarter 2024 Financial Results - The Manila Times

Oct 31, 2024
pulisher
Oct 30, 2024

Earnings Preview: Agios Pharmaceuticals - Benzinga

Oct 30, 2024
pulisher
Oct 30, 2024

Leerink Partnrs Issues Optimistic Estimate for AGIO Earnings - MarketBeat

Oct 30, 2024
pulisher
Oct 25, 2024

Analysts Are Optimistic We'll See A Profit From Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Simply Wall St

Oct 25, 2024
pulisher
Oct 25, 2024

Equities Analysts Set Expectations for AGIO Q3 Earnings - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Pfizer Pulls Key Sickle Cell Drug Over Safety Concerns - Finimize

Oct 25, 2024
pulisher
Oct 24, 2024

Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts By Investing.com - Investing.com Australia

Oct 24, 2024
pulisher
Oct 24, 2024

Agios Pharmaceuticals (AGIO) Set to Announce Quarterly Earnings on Thursday - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts - Investing.com India

Oct 24, 2024
pulisher
Oct 24, 2024

Servier vorasidenib PDUFA near, Agios wins in thalassemia - BioWorld Online

Oct 24, 2024
pulisher
Oct 24, 2024

Agios completes enrollment for sickle cell disease trial By Investing.com - Investing.com Canada

Oct 24, 2024
pulisher
Oct 23, 2024

Agios completes enrollment for sickle cell disease trial - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease - The Manila Times

Oct 23, 2024
pulisher
Oct 22, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Oct 22, 2024
pulisher
Oct 19, 2024

(AGIO) Investment Report - Stock Traders Daily

Oct 19, 2024
pulisher
Oct 17, 2024

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024 - StockTitan

Oct 17, 2024
pulisher
Oct 17, 2024

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024 - GlobeNewswire Inc.

Oct 17, 2024
pulisher
Oct 16, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded by StockNews.com to Hold - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Scotiabank Initiates Coverage on Agios Pharmaceuticals (NASDAQ:AGIO) - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Beta Thalassemia Market to Show Remarkable Growth Trends from - openPR

Oct 15, 2024
pulisher
Oct 15, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Update - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

Leerink keeps market perform rating on Agios Pharma shares amid SCD drug concerns - Investing.com Canada

Oct 15, 2024
pulisher
Oct 14, 2024

SG Americas Securities LLC Invests $705,000 in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat

Oct 14, 2024
pulisher
Oct 12, 2024

Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio? - MSN

Oct 12, 2024
pulisher
Oct 11, 2024

AQR Capital Management LLC Increases Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat

Oct 11, 2024
pulisher
Oct 10, 2024

Agios Pharma stock raised to Outperform By Investing.com - Investing.com UK

Oct 10, 2024
pulisher
Oct 10, 2024

4 Analysts Have This To Say About Agios Pharmaceuticals - Benzinga

Oct 10, 2024
pulisher
Oct 10, 2024

Raymond James Reiterates Outperform Rating for Agios Pharmaceuticals (NASDAQ:AGIO) - MarketBeat

Oct 10, 2024
pulisher
Oct 08, 2024

Sei Investments Co. Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat

Oct 08, 2024
pulisher
Oct 07, 2024

The Manufacturers Life Insurance Company Has $5.94 Million Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat

Oct 07, 2024
pulisher
Oct 01, 2024

Alpha Thalassemia Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharma - Barchart

Oct 01, 2024

Agios Pharmaceuticals Inc Azioni (AGIO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Agios Pharmaceuticals Inc Azioni (AGIO) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Jones Cecilia
Chief Financial Officer
Sep 26 '24
Sale
49.03
2,542
124,634
20,158
Ballal Rahul D.
Director
Aug 11 '24
Option Exercise
0.00
2,302
0
7,992
Smith Cynthia
Director
Aug 11 '24
Option Exercise
0.00
2,302
0
7,992
Goff Brian
Chief Executive Officer
Aug 08 '24
Option Exercise
0.00
22,691
0
89,883
Goff Brian
Chief Executive Officer
Aug 08 '24
Sale
42.75
11,091
474,140
78,792
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Capitalizzazione:     |  Volume (24 ore):